Abstract 953
Background
The anti-cancer activity of 5-FU, and its other forms: floxuridine and capecitabine, is largely attributable to its active metabolite, fluorodeoxyuridine-monophosphate (FUDR-MP) that inhibits the enzyme thymidylate synthase (TS) and depletes the dTMP pool essential for cancer cell replication. Although 5-FU based agents remain the cornerstone of treatment for many tumour types, key cellular resistance mechanisms of breakdown, activation and transport limit their effectiveness. NUC-3373 is a phosphoramidate transformation of FUDR-MP designed to bypass these resistance pathways. It efficiently inhibits TS and depletes the dTMP pool within 2-4 hours. NUC-3373 is resistant to dihydropyrimidine dehydrogenase-mediated degradation and does not generate the toxic metabolite dhFU. NUC3373 has an advantageous PK/PD profile compared to 5-FU, with plasma t1/2=9.7 h vs 8-14 mins, enabling the study of a more convenient alternate weekly dose-scheduling (Ghazaly et al ESMO, 2017).
Trial design
The primary study objective is to determine the RP2D and schedule of NUC3373 in patients with advanced cancers. Secondary objectives include safety, anti‐tumour activity and PK/PD. In Part I, NUC‐3373 was administered as an IV infusion on days 1, 8, 15 and 22 of a 28‐day cycle. In Part II, NUC-3373 was administered on days 1 and 15 of a 28‐day cycle. For PK analyses, blood samples were collected at 12 timepoints up to 48 h post‐dose during cycle 1. Plasma and intracellular metabolites were measured by UPLC-MS/MS. Levels of free and bound TS were measured in PBMCs by western blotting. To date, thirty-six patients have been enrolled: Part I n = 29; Part II n = 7. Dose escalation is ongoing to establish the RP2D. Cohorts in Part I received NUC-3373 at 125, 250, 500, 750, 1125 and 1500 mg/m2 and cohorts in Part II at 1500 and 1875 mg/m2.
Clinical trial identification
NCT02723240.
Legal entity responsible for the study
Nucana plc.
Funding
Nucana plc.
Editorial Acknowledgement
Disclosure
S. Blagden: Advisor: Ellipses, Director of RNA Guardian Ltd.; Advisory boards: Clovis and Novartis; Research funding Nucana plc (unrelated to NUC-3373). T.R.J. Evans: Institution receives financial support for the costs of conducting this clinical trial and other studies with another of Nucana's compounds. Institution has also been reimbursed for time in a one-off advisory board for Nucana for another of their compounds. All other authors have declared no conflicts of interest.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract